<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="8589" end="8593" sStart="8515" offset="74" sid="r11.true.j.0381" wn="1" wnkey="true%3:00:00::" text="Large organs shrink more rapidly than smaller ones, and this is true regardless of the dose that is used [13]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="4362" end="4367" sStart="null" offset="169" sid="r7.sound.n.0013" wn="2147483645" wnkey="null" text="Many of the patients studied did not live near Bethesda, and it is likely that the dose schedule that was chosen was based on convenience rather than on sound pharmacokinetic principles." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="4362" end="4367" sStart="null" offset="169" sid="r7.sound.n.0013" wn="2147483645" wnkey="null" text="Many of the patients studied did not live near Bethesda, and it is likely that the dose schedule that was chosen was based on convenience rather than on sound pharmacokinetic principles." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="4362" end="4367" sStart="null" offset="169" sid="r7.sound.n.0013" wn="2147483645" wnkey="null" text="Many of the patients studied did not live near Bethesda, and it is likely that the dose schedule that was chosen was based on convenience rather than on sound pharmacokinetic principles." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="4362" end="4367" sStart="null" offset="169" sid="r7.sound.n.0013" wn="2147483645" wnkey="null" text="Many of the patients studied did not live near Bethesda, and it is likely that the dose schedule that was chosen was based on convenience rather than on sound pharmacokinetic principles." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="8307" end="8313" sStart="null" offset="39" sid="r11.severe.j.0074" wn="5" wnkey="severe%5:00:00:critical:03" text="It is often assumed that patients with severe disease require larger doses of enzyme than those with mild disease, but a meta-analysis based on liver size or spleen size made it clear that this is not the case (Figure 3) [12]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="8307" end="8313" sStart="null" offset="39" sid="r11.severe.j.0074" wn="5" wnkey="severe%5:00:00:critical:03" text="It is often assumed that patients with severe disease require larger doses of enzyme than those with mild disease, but a meta-analysis based on liver size or spleen size made it clear that this is not the case (Figure 3) [12]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="11500" end="11506" sStart="null" offset="23" sid="r7.serve.v.0861" wn="1" wnkey="serve%2:42:03::" text="This profitability has served as a stimulus for the development of enzyme replacement treatments for diseases less common and generally less responsive to treatment than Gaucher disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="8019" end="8024" sStart="null" offset="199" sid="r11.refer.v.0457" wn="1" wnkey="refer%2:32:01::" text="Having said this, I recognize that most, but not all, of the patients that were included in our meta-analyses were adults, whereas the company-sponsored consensus recommendations refer to children." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="7324" end="7336" sStart="null" offset="31" sid="r11.recommend.v.0773" wn="1" wnkey="recommend%2:32:01::" text="The only support for recommending this high dosage comes from uncontrolled studies showing that in some children bone lesions may progress at low dosages." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010021.anc" start="8758" end="8763" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The response of enlarged viscera to enzyme infusion is much more &lt;b&gt;rapid&lt;/b&gt; than the response of bones." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010021.anc" start="8758" end="8763" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The response of enlarged viscera to enzyme infusion is much more &lt;b&gt;rapid&lt;/b&gt; than the response of bones." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="12052" end="12056" sStart="null" offset="31" sid="r8.life.n.0309" wn="10" wnkey="life%1:03:00::" text="We do not put a price on human life." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="705" end="709" sStart="null" offset="163" sid="r8.life.n.0399" wn="5" wnkey="life%1:28:00::" text="The disease may be discovered as an incidental finding in the elderly because of mild thrombocytopenia or splenomegaly, or it may present early in life with hepatosplenomegaly, thrombocytopenia, anemia, and bone lesions." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="1258" end="1262" sStart="null" offset="14" sid="r10.high.j.0193" wn="1" wnkey="high%3:00:02::" text="Moreover, the high cost of enzyme replacement therapy forces us to consider what society can afford in the way of palliative treatments for very rare diseases." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="61" end="67" sStart="null" offset="28" sid="r10.common.j.0867" wn="4" wnkey="common%5:00:00:familiar:02" text="Gaucher disease is the most common lysosomal storage disorder (Box 1)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="1931" end="1937" sStart="null" offset="33" sid="r10.common.j.0511" wn="4" wnkey="common%5:00:00:familiar:02" text="Type 1 Gaucher disease, the most common type, seems a particularly suitable target for enzyme replacement therapy because of the lack of central nervous system involvement (visceral damage in Gaucher disease is reversible whereas the brain damage usually is not)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="11600" end="11606" sStart="null" offset="123" sid="r10.common.j.0299" wn="4" wnkey="common%5:00:00:familiar:02" text="This profitability has served as a stimulus for the development of enzyme replacement treatments for diseases less common and generally less responsive to treatment than Gaucher disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="10018" end="10024" sStart="null" offset="60" sid="r10.common.j.0796" wn="4" wnkey="common%5:00:00:familiar:02" text="In children, the situation is different, and progression is common." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010021.anc" start="8054" end="8061" sStart="null" offset="16" sid="r11.absence.n.0354" wn="1" wnkey="absence%1:26:00::" text="However, in the absence of any evidence-based rationale for administering large, costly doses of enzyme, I believe that the use of smaller, more frequent doses is the most prudent treatment approach." />
  </sentences>
</list>